Could Roche’s Molecular Glue Deal Signal a New Drug Discovery Race?

Drug discovery in molecular glues is attracting renewed attention as pharmaceutical companies seek new ways to target disease-driving proteins. Roche’s research collaboration with China’s Defand Therapeutics, announced on 8 October 2026, adds a major player to this emerging field.

The agreement combines Defand’s discovery platform with Roche’s development and commercial capabilities, highlighting how pharmaceutical companies are securing access to new drug candidates earlier in the research process.

Image

Why Could Drug Discovery in Molecular Glues Gain Real Ground?

Traditional small-molecule medicines often work by binding to a specific site on a protein and changing its activity. This approach has produced many important therapies. However, it can struggle when a disease-driving protein lacks a suitable binding pocket or performs its biological role through complex interactions with other proteins.

Molecular glues offer a completely different approach to drug discovery.

These small molecules can encourage two proteins to interact when they would not normally form a stable partnership.

In targeted protein degradation, this interaction can incorporate a disease-associated protein into contact with an E3 ubiquitin ligase, an enzyme complex involved in marking proteins for disposal.

The cell then attaches ubiquitin molecules to the recruited protein. This signal can direct it to the proteasome, the cellular machinery that breaks down unwanted or damaged proteins.

Rather than simply blocking a protein’s activity, a molecular glue degrader can prompt the cell to remove the protein itself.

A 2025 review in Nature Reviews Cancer describes how targeted protein degradation has advanced through improved structural biology, mechanistic understanding, and the development of new degrader designs.

These advances are expanding the scientific basis for designing medicines that redirect the cell’s own protein-control systems.

This could mark important breakthroughs for drug discovery because while some proteins lack the conventional binding sites that medicinal chemists rely on when developing inhibitors, molecular glues change the interaction surface between proteins rather than requiring a compound to occupy a conventional pocket on the disease target.

The commercial opportunity lies in discovering new biological interactions that can be turned into medicines.

Yet the possibility of targeting a previously inaccessible protein does not always guarantee that a useful drug can be developed. Researchers must still establish selectivity, suitable exposure, safety, and meaningful biological activity.

Read Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.

The Roche and Defand Molecular Glue Collaboration

According to the 8 October announcement reported by Fineline Cube, Roche and Hangzhou-based Defand Therapeutics have entered a research collaboration and licensing agreement covering multiple targets in oncology and immunology.

The reported structure divides responsibilities between discovery and subsequent development.

Defand will use its proprietary high-throughput degrader screening platform to identify molecular glue candidates against designated targets, while Roche will take responsibility for subsequent preclinical and clinical development with exclusive global commercialisation rights under the agreement.

Roche also has an option to expand the collaboration to additional targets, according to the report. The parties have not publicly disclosed the specific financial terms.

Industry-quoted sources have estimated that the collaboration could be worth close to US$1 billion, including potential milestone payments. 

The agreement reflects a division of labour that can make sense for early-stage drug discovery.

A specialist biotechnology company can concentrate resources on platform development, screening, and the identification of promising compounds. A global pharmaceutical partner can contribute experience in candidate selection, toxicology, clinical development, regulatory strategy, manufacturing, and commercialisation.

For Defand, the collaboration offers a route to advance its technology through programmes supported by Roche’s clinical development infrastructure. Potential milestone payments and royalties could also provide future financial returns if compounds meet specified development objectives and eventually reach the market.

For Roche, the arrangement creates access to an external discovery platform without requiring the company to develop every element of the technology internally. It also gives Roche an opportunity to select candidates for further investment as evidence emerges.

This is consistent with Roche’s broader research technology partnering priorities, including novel modalities that expand the range of druggable targets.

Roche also lists its existing collaboration with Orionis Biosciences to discover small-molecule medicines, including molecular glues, for difficult targets in oncology and neurodegeneration.

The Defand agreement therefore adds to an established interest in the modality.

Image

How Do Molecular Glues Differ From Other Protein Degraders?

Molecular glues form part of the broader field of targeted protein degradation, alongside proteolysis-targeting chimeras (PROTACs).

Both approaches can redirect the cell’s protein-disposal machinery, but their molecular designs differ.

A PROTAC typically contains two binding elements connected by a linker. One element binds the target protein, while the other recruits an E3 ubiquitin ligase. This creates a bridge that brings the two proteins into proximity.

A molecular glue, on the other hand, is generally smaller and acts by stabilising or inducing a protein-protein interaction.

It does not necessarily require a separate, high-affinity binding element for each protein. Instead, its chemistry helps create a favourable interface between the proteins involved.

This difference creates distinct discovery opportunities and challenges.

• Molecular glues may offer compact structures and access to targets for which conventional binding compounds are difficult to find. However, researchers must identify compounds that induce the right interaction and produce a useful biological effect.
• PROTACs provide a more explicitly modular design strategy, but their larger molecular structures can create challenges for cell penetration, absorption, distribution, and other drug-like properties.
• Both approaches require evidence that degradation is sufficiently selective, that the target matters to the disease, and that the resulting pharmacology can be tolerated in patients.

Both drug discovery from molecular glues and PROTACs have progressed from chemical biology research towards clinical investigation. The field now includes several degrader programmes, but the relative advantages of each approach depend on the target, compound, disease setting, and desired pharmacological effect.

Molecular glues also have a history in established medicines. Thalidomide derivatives, including immunomodulatory drugs used in multiple myeloma, can redirect cereblon, an E3 ubiquitin ligase substrate receptor, towards proteins that it would not normally recognise in the same way.

This provides clinical precedent for manipulating protein interactions to alter protein abundance.

However, not every molecular glue acts by degrading a protein. Some stabilise interactions or alter protein function without triggering degradation.

Roche and Defand’s reported focus is specifically on molecular glue degraders, so the relevant question is whether their platform can identify compounds that produce the desired degradation profile against selected disease targets.

Read First Quarter 2026 State of Digital Health Funding

First Quarter 2026 State of Digital Health Funding

Digital health funding hit $7.4B in Q1 2026, the highest since Q2 2022. The CB Insights State of Digital Health report reveals where capital is concentrating and why it matters for pharma leaders.

Image

How Much of a Challenge Is Finding the Right Glue?

The central scientific challenge is to discover a molecule that creates the right interaction between proteins, in the right biological context, with enough selectivity to support a medicine.

Historically, many molecular glues emerged through observations that researchers later traced back to unexpected changes in protein interactions. Advances in structural biology, chemical screening, proteomics, and computational methods are helping researchers investigate these effects more systematically.

Defand’s reported high-throughput degrader screening platform is relevant because molecular glue discovery involves a broad search problem. A useful screening system must identify compounds that do more than generate an apparent interaction.

Researchers need to determine whether a candidate recruits the intended proteins, causes degradation of the target, and produces a disease-relevant effect.

Several questions will determine whether a discovery programme can progress:

• Target biology: Does reducing the target protein produce a meaningful therapeutic effect, and could the same intervention harm healthy cells?
• Selectivity: Does the compound degrade the intended protein without disrupting other proteins in ways that could cause toxicity?
• Mechanism: Can researchers demonstrate the relevant protein interaction and establish that degradation drives the observed effect?
• Drug-like properties: Can the compound reach the relevant tissue, enter the necessary cells, and achieve sufficient exposure?
• Resistance and durability: Could cells adapt by changing the target, the recruited ligase, or another part of the degradation pathway?

These questions require complementary methods to answer.

Proteomics can help identify proteins whose abundance changes after treatment; genetic experiments can test whether the proposed target or ligase is necessary for the effect; structural studies can clarify how the compound stabilises the protein complex, and pharmacology and toxicology then help establish whether the mechanism has a viable therapeutic window.

High-throughput screening can accelerate the initial search, but it does not remove the need for careful confirmation. 

Image

What Does the Roche-Defand Deal Mean for Drug Discovery Involving Molecular Glues?

The Roche–Defand collaboration illustrates a wider change in how pharmaceutical companies access innovation. Rather than acquiring only an asset with established preclinical or clinical data, a company can partner with a specialist to discover multiple candidates against selected targets.

This structure provides optionality across a discovery portfolio.

The pharmaceutical partner can support programmes as evidence develops, while retaining the ability to direct later investment towards candidates that meet scientific and commercial criteria. An option to add further targets can extend that opportunity if the initial collaboration proves productive.

The model also shifts part of the early discovery work to a specialist partner. That can improve access to focused technical capabilities, but it leaves important uncertainties unresolved.

The collaboration’s value will depend on the quality of the targets, the performance of the screening platform, and the number of candidates that survive the transition from discovery into preclinical development.

For molecular glues in oncology and immunology, the therapeutic rationale is substantial. Both fields contain disease-driving proteins that are difficult to inhibit selectively, and both involve complex signalling networks in which protein abundance can influence disease behaviour.

Nevertheless, the same degradation mechanism can have different effects across tissues and disease contexts. Each programme will need its own evidence base.

The partnership also reflects the growing role of Chinese biotechnology companies in global pharmaceutical research. Roche’s Asia partnering strategy explicitly seeks opportunities with biotechnology companies and academic institutions in the region, including early-stage programmes and technologies relevant to oncology, immunology, and molecular glues.

For business development teams, the important aspect is whether the collaboration generates differentiated drug discovery compounds, establishes convincing mechanisms, and advances suitable candidates towards development milestones.

Can external platforms reliably deliver discoveries that internal teams could not produce as efficiently on their own? For investors, milestone-based deal structures relying on this require careful interpretation because the maximum potential value depends on future events that may never occur.

At Pharmatica, we explore the scientific platforms, partnerships, and investment decisions shaping Therapeutic Drug Discovery. Roche’s agreement with Defand highlights both the promise of molecular glue degraders and the work still needed to turn a promising discovery technology into medicines for patients.

Pharmatica: Insight. Connection. Impact.